In recent years, along with the reported beneficial effects of sodium-glucose cotransporter-2 inhibitor treatment on kidneys (20, 21), elucidating the pathogenesis of kidney disease from the perspective of ketogenesis has been increasingly appreciated. Here, SLC5A2 is linked to kidney disorder.